Spero Therapeutics EV/EBIT SPRO

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Oct 23, 2026: 2.1×
3-year median: 2.1×
Against its 3-year history: 50th; percentile: 0 is its lowest day, 100 its highest
3-year range: 0.0× to 16.8×
Peer median: 3.5×

Spero Therapeutics' EV/EBIT is 2.1× as of Oct 23, 2026.

That is above its 3-year median of 2.1×, close to the middle of its last 3 years.

Over that time it ranged from 0.0× in Nov 2024 to 16.8× in Apr 2026.

The median for 8 large drugmakers of a similar size is 3.5×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.1×	0.8×	16.8×
2025	n/m a value too high to mean anything
2024	0.4×	0.0×	0.8×

Against its peers

Companies in Drug Manufacturers - General nearest Spero Therapeutics' size, closest first, today.

Company	EV/EBIT
SPROSpero Therapeutics	2.1×
LFVNLifevantage	9.6×
ATNMActinium Pharmaceuticals	1.2×
NATRNatures Sunshine Products	5.2×
ARVNArvinas	n/m
PBYIPuma Biotechnology	15.6×
IRWDIronwood Pharmaceuticals	3.5×
ZVRAZevra Therapeutics	2.9×
CRMDCorMedix	2.3×
Peer median	3.5×

Where Spero Therapeutics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Spero Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.